Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY – Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 390 shares, an increase of 333.3% from the September 30th total of 90 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 19 shares, the days-to-cover ratio is currently 20.5 days.
Analyst Ratings Changes
Separately, UBS Group downgraded Ambu A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 15th. One analyst has rated the stock with a Hold rating. According to MarketBeat.com, Ambu A/S currently has a consensus rating of “Hold”.
Check Out Our Latest Analysis on AMBBY
Ambu A/S Stock Performance
Ambu A/S stock opened at $11.64 on Thursday. The company has a market cap of $2.74 billion, a price-to-earnings ratio of 38.80 and a beta of 0.92. Ambu A/S has a 12 month low of $8.54 and a 12 month high of $16.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.77 and a quick ratio of 1.69. The stock’s 50-day moving average is $11.00 and its 200-day moving average is $11.04.
Ambu A/S (OTCMKTS:AMBBY – Get Free Report) last posted its earnings results on Tuesday, August 25th. The company reported $0.09 earnings per share (EPS) for the quarter. Ambu A/S had a net margin of 8.18% and a return on equity of 8.49%. The firm had revenue of $255.12 million during the quarter.
About Ambu A/S
Ambu A/S is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. Its products are designed to support clinical procedures while reducing the need for cleaning, disinfection and reprocessing associated with reusable equipment.
The company’s portfolio includes single-use endoscopy systems, such as the aScope range of flexible endoscopes and related visualization equipment, as well as products for anesthesia, airway management, ventilation, resuscitation and patient monitoring.
Further Reading
- Five stocks we like better than Ambu A/S
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
